Enteropathic arthritis in Brazil: data from the Brazilian registry of spondyloarthritis


*Corresponding author.
E-mail: gustavogomesresende@yahoo.com.br (G.G. Resende).
0482-5004/$ - see front matter. © 2013 Elsevier Editora Ltda. All rights reserved. http://dx.doi.org/10.1016/j.rbre.2013.04.001
Artrite enteropática no Brasil: dados do registro brasileiro de espondiloartrites

Keywords:
Artrite enteropática
Doença de Crohn
Retocolite ulcerativa
Estudos de registro

ARTICLE INFO
Article history:
Received on June 2, 2012
Accepted on April 4, 2013

ABSTRACT
Inflammatory bowel diseases (Crohn’s disease and ulcerative rectocolitis) have extraintestinal manifestations 25% of the patients, with the most common one being the entero-pathic arthritis.

Methods: Prospective, observational, multicenter study with patients from 29 reference centers participating in the Brazilian Registry of Spondyloarthritis (RBE), which incorporates the RESPONDIA (Ibero-American Registry of Spondyloarthritis) group. Demographic and clinical data were collected from 1472 patients and standardized questionnaires for the assessment of axial mobility, quality of life, enthesitic involvement, disease activity and functional capacity were applied. Laboratory and radiographic examinations were performed. The aim of this study is to compare the clinical, epidemiological, genetic, imaging, treatment and prognostic characteristics of patients with enteropathic arthritis with other types of spondyloarthritis in a large Brazilian cohort.

Results: A total of 3.2% of patients were classified as having enteropathic arthritis, 2.5% had spondylitis and 0.7%, arthritis (peripheral predominance). The subgroup of individuals with enteropathic arthritis had a higher prevalence in women ($P < 0.001$), lower incidence of inflammatory axial pain ($P < 0.001$) and enthesitis ($P = 0.004$). HLA-B27 was less frequent in the group with enteropathic arthritis ($P = 0.001$), even when considering only those with the pure axial form. There was a lower prevalence of radiographic sacroiliitis ($P = 0.009$) and lower radiographic score (BASRI) ($P = 0.006$) when compared to patients with other types of spondyloarthritis. They also used more corticosteroids ($P < 0.001$) and sulfasalazine ($P < 0.001$) and less non-steroidal anti-inflammatory drugs ($P < 0.001$) and methotrexate ($P = 0.001$).

Conclusion: There were differences between patients with enteropathic arthritis and other types of spondyloarthritis, especially higher prevalence of females, lower frequency of HLA-B27, associated with less severe axial involvement.

© 2013 Elsevier Editora Ltda. All rights reserved.

R E S U M O
As doenças inflamatórias intestinais (doença de Crohn e retocolite ulcerativa) apresentam manifestações extraintestinais em um quarto dos pacientes, sendo a mais comum a artrite enteropática.

Métodos: Estudo prospectivo, observacional e multicêntrico, realizado com pacientes de 29 centros de referência participantes do Registro Brasileiro de Espondiloartrites (RBE), que se incorpora ao grupo RESPONDIA (Registro Ibero-americano de Espondiloartrites). Dados demográficos e clínicos de 1472 pacientes foram colhidos, e aplicaram-se questionários padronizados de avaliação de mobilidade axial, qualidade de vida, enthesite, doença, atividade e capacidade funcional. Exames laboratoriais e radiográficos foram realizados. Objetivamos, neste presente artigo, comparar as características clínicas, epidemiológicas, genéticas, imunológicas, de tratamento e prognóstico de enteropatias com os outros espondiloartríticos nesta grande coorte brasileira.

Resultados: Foram classificados como enteropatite 3,2% dos pacientes, sendo que 2,5% tinham espondilitis e 0,7%, artrite (predominio periférico). O subgrupo de indivíduos com enteropatite apresentava maior prevalência de mulheres ($P < 0,001$), menor incidência de dor axial inflamatória ($P < 0,001$) e de entesite ($P = 0,004$). O HLA-B27 foi menos frequente no grupo de enteropatitas ($P = 0,001$), mesmo se considerado apenas aqueles com a forma axial pura. Houve menor prevalência de sacroilite radiológica ($P = 0,009$) e também menor escore radiográfico (BASRI) ($P = 0,006$) quando comparado aos pacientes com as demais espondiloartíticas. Também fizeram mais uso de corticosteroides ($P < 0,001$) e sulfasalazina ($P < 0,001$) e menor uso de anti-inflamatórios não hormonais ($P < 0,001$) e metotrexato ($P = 0,001$).
Introduction

Inflammatory bowel disease (IBD) is the term currently used to designate two diseases considered idiopathic to date: Crohn’s disease (CD) and ulcerative rectocolitis (URC). Although grouped together, the two can be differentiated by defined clinical, endoscopic, histological, and etiopathogenic characteristics.

Both diseases affect men and women equally and have a peak incidence in the second and third decades of life; the prevalence of each is estimated at 25-250 per 100,000 individuals, with a slight predominance of URC. Their main symptoms are diarrhea, abdominal pain, and gastrointestinal bleeding, in addition to systemic symptoms such as fever, weight loss, and fatigue. They often have an intermittent course, alternating periods of exacerbation and remission.

CD is characterized by transmural (granulomatous in only approximately 30%) and discontinuous inflammation of the digestive tract, and it affects mainly the distal small intestine (ileum), but with potential to reach any other segment, from the mouth to the anus. Due to its tendency to cause fibrosis, it can lead to stenosis and obstruction, and because of the possibility of micro-perforations, fistulas may appear.

URC, in turn, is characterized by a superficial and continuous involvement of the colonic mucosa, almost invariably involving the rectum and sometimes extending proximally. It is usually classified (regarding the severity and extent of involvement) as mild when only the rectum or rectosigmoid are affected (proctitis or proctosigmoiditis); as moderate, when the descending colon is also affected (left colitis); and as severe, when it reaches the cecum (pancoitis).

Other extraintestinal manifestations can be associated to IBD in approximately 25% of patients; the most common are those caused by joint (axial or peripheral), eye (uveitis and episcleritis), skin (erythema nodosum and pyoderma gangrenosum), and biliary tract (sclerosing cholangitis) involvement. These symptoms may precede, coexist with, or follow the intestinal manifestations.1-4

Enteroarthritis is the most common extraintestinal manifestation of IBD, whose prevalence varies from 14% to 44%.5-8 It has two main patterns of clinical expression: the peripheral and axial forms. The first can be divided into two subgroups: type I, which is often self-limited, oligoarticular (< five joints involved), accompanies outbreaks of intestinal inflammatory activity, and is not associated with the presence of HLA-B27; and type II, polyarticular, usually follows an independent course from the intestinal disease. The latter rarely becomes chronic. The axial form can include sacroiliitis and/or spondylitis unrelated to the bowel disease activity, and may even precede its onset by years.9-12 This is associated with the presence of HLA-B27 in 50% to 75% of cases – a similar frequency, although lower, than that found in idiopathic spondylitis.13-15

There is often some overlapping between these forms, and periarticular involvement is possible, whether of the entheses, tendons, or the periostium.16-18

CARD15 gene polymorphisms have been associated with an increased risk of developing CD, and are considered predictors of both chronic inflammatory bowel disease in patients with spondyloarthritis and sacroiliitis in those with CD. This gene encodes an intracellular protein expressed in several cell types, which act as receptor for components of bacterial cell wall, and is involved in the activation of nuclear factor kappaβ (NF-κβ) and apoptosis.8,19,20

In this article, the main characteristics of the sample of enteropathic arthritis of the Brazilian Registry of Spondyloarthropathy (Registro Brasileiro de Espondiloartrites – RBE) are discussed.

Methods

This was a prospective, observational, multicenter study, conducted with patients from 29 reference centers participating in the RBE. All patients met the criteria of the European Spondyloarthritis Study Group (ESSG).21 Data were collected from June 2006 to December 2009. The RBE is a member of the Ibero-American Registry of Spondyloarthritis (RESPONDIA) group, which consists of nine Latin American countries (Argentina, Brazil, Costa Rica, Chile, Ecuador, Mexico, Peru, Uruguay, and Venezuela) and the two countries of the Iberian Peninsula (Spain and Portugal).

In this study, a standard protocol was applied to the 1,472 patients. The diagnosis of enteroarthritis was considered when a patient had peripheral or axial inflammatory joint involvement associated with CD or URC, diagnosed by a physician and confirmed by radiographic or endoscopic examination.

Demographic and clinical data were collected, and the following questionnaires, previously translated and validated for Brazilian Portuguese) were applied: Bath Ankylosing Spondylitis Metrologic Index (BASMI), to assess spinal mobility;16 Ankylosing Spondylitis Quality of Life (ASQoL), to assess quality of life;23 Maastricht Ankylosing Spondylitis enthesitis score (MASES), to assess enthesic involvement;24 Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), to assess disease activity,25 and Bath Ankylosing Spondylitis Functional Index (BASFI) to assess functional capacity.26

Laboratory test results (HLA-B27, erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) were also recorded, as well as radiographs of the cervical and lumbosacral spine and the sacroiliac and coxofemoral joints. Radiological damage was evaluated using the Bath Ankylosing Spondylitis Radiologic Index (BASRI).27
**Statistical analysis**

Pearson’s chi-squared test was used to analyze the association between enteroarthritis and categorical variables, and Student’s t-test was used to compare means of numerical variables between patients with enteroarthritis and other types of spondyloarthritis. An alpha of 5% was used in all tests: those with $P < 0.05$ were considered to be statistically significant.

**Results**

Of a total of 1,472 patients, 65.4% ($N = 963$) were classified as having ankylosing spondylitis (AS), 18.4% ($N = 271$) as psoriatic arthritis (PA), 6.7% ($N = 98$) as undifferentiated spondyloarthritis (USpA), 3.3% ($N = 49$) as reactive arthritis (ReA), and 3.2% ($N = 48$) as enteropathic arthritis (EA), with 2.5% ($N = 7$) of spondylitis associated with IBD and 0.7% ($N = 11$) of arthritis associated with IBD. Also, 2.9% were classified as having juvenile spondyloarthritis (JSaP) (Fig. 1).

Regarding the clinical forms identified among individuals with enteroarthritis, it was observed that the overlapping (mixed form, with both axial and peripheral involvement) was the most common phenotype with 52.5%, followed by the pure axial with 27.5%; isolated peripheral form, with 17.5%; and enthesitic form, without axial or peripheral joint involvement, with 2.5% (Fig. 2).

When comparing the clinical characteristics (Table 1) of the enteroarthritis group and of other types of spondyloarthritis, a statistically significant difference was observed regarding the higher frequency of females ($P < 0.001$) and the lower frequency of inflammatory axial pain ($P < 0.001$) and of enthesitis ($P = 0.004$) in patients with enteropathic arthritis.

Patients with enteropathic arthritis showed lower mean disease duration (9.6 years vs. 14.1 years, $P = 0.005$), fewer inflamed joints (0.77 vs. 1.61, $P = 0.004$), as well as better rates of mobility in the lumbar spine (mean lateral lumbar flexion of 31.5 cm vs. 25.4 cm, $P = 0.03$; and Schober index of 6.2 cm...
No statistical difference was observed between the prevalence of extra-articular manifestations, although there was a trend of lower incidence of ocular disease (anterior uveitis) in patients with enteropathic arthritis (10.4% vs. 20.3% in other types of spondyloarthritis, P = 0.092) (Table 1).

Positivity for HLA-B27 was also statistically significant, with a lower frequency in patients with enteropathic arthritis (P = 0.001). There was also a statistical difference in CRP measurements between the two groups, with lower values among those with enteropathic arthritis (5.48 mg/L vs. 10.29 mg/L, P = 0.001). Conversely, the latter showed a statistical trend to higher values of ESR (31.3 mm vs. 24.7 mm, P = 0.08).

Regarding radiographic alterations, there was a lower prevalence of radiographic sacroiliitis, considering at least grade II bilateral or III unilateral (modified New York criteria) in individuals from the enteroarthritis group (60.4% vs. 76.8% P = 0.009). BASRI scores were also lower, with a mean of 5.2 and 7.1 in enteroarthritis and other diseases (P = 0.006), respectively and of the BASRI coxofemoral-component (0.6 vs. 1.2; P = 0.001).

No statistical differences were observed between the two groups regarding professional activity, work disability, exercise habits, or ASQoL, BASDAI, BASFI, and MASES scores (Table 2).

As for the therapeutic regimens used (Table 3), a more frequent use of corticosteroids was observed (62.5% vs. 34.6%; P < 0.001) and less frequent use of nonsteroidal anti-inflammatory drugs (NSAIDs) (43.8% vs. 68.2%; P < 0.001). There was also a difference regarding the evaluation of NSAIDs efficacy by patients. In the enteroarthritis group, only 35.4% of the patients described NSAIDs as being effective (i.e., capable of effectively improving pain within 48 hours), compared with 69.3% of individuals with the other diseases (P < 0.001). There is a limitation on the scoring for this comparison, since different drug doses and regimens were grouped under the same category.

Among the disease-modifying antirheumatic drugs (DMARDs), there was also a statistical difference between the use of methotrexate (with lower use in enteroarthritis, 29.2% vs. 52.6%, P = 0.001) and sulfasalazine (with greater use in this group, 79.2% vs. 43.2 %, P < 0.001). Among the anticytokine agents, infliximab showed only a statistical trend in the frequency of use between the groups (use in the enteroarthritis group, 25%, and in other diseases, 15%, P = 0.057). There was no difference between the groups regarding the use of other anti-TNF agents, adalimumab, and etanercept; it is noteworthy that the latter drugs were introduced more recently in Brazil.

### Table 2 – Comparison of laboratory tests, imaging studies and disease rates in patients with enteropathic arthritis and other types of spondyloarthritis.

<table>
<thead>
<tr>
<th>Brazilian Registry of Spondyloarthritis</th>
<th>Enteroarthritis</th>
<th>Spondyloarthritis P</th>
</tr>
</thead>
<tbody>
<tr>
<td>HLA-B27 (N/%)</td>
<td>10/38.5</td>
<td>492/70.1</td>
</tr>
<tr>
<td>CRP (mean; mg/L)</td>
<td>5.49</td>
<td>10.29</td>
</tr>
<tr>
<td>ESR (mean; mm)</td>
<td>31.3</td>
<td>24.7</td>
</tr>
<tr>
<td>BASDAI (mean)</td>
<td>4.62</td>
<td>4.18</td>
</tr>
<tr>
<td>BASFI (mean)</td>
<td>4.77</td>
<td>4.54</td>
</tr>
<tr>
<td>MASES (mean)</td>
<td>1.9</td>
<td>2.1</td>
</tr>
<tr>
<td>High-grade radiological sacroilitis*</td>
<td>29/60.4%</td>
<td>1,119/76.8%</td>
</tr>
<tr>
<td>BASRI-column (N/%)</td>
<td>4.8</td>
<td>5.9</td>
</tr>
<tr>
<td>BASRI-coxofemoral (mean)</td>
<td>0.6</td>
<td>1.2</td>
</tr>
<tr>
<td>BASRI-total (mean)</td>
<td>5.2</td>
<td>7.1</td>
</tr>
</tbody>
</table>

**Note:** The mere presence of sacroilitis at plain radiography, graded as at least grade II bilateral or unilateral grade III.

### Table 3 – Description of the medications used and their frequency in patients with enteropathic arthritis and other types of spondyloarthritis.

<table>
<thead>
<tr>
<th>Brazilian Registry of Spondyloarthritis</th>
<th>Use of NSAIDs (N/%)</th>
<th>Efficacy of</th>
<th>Corticosteroids (N/%)</th>
<th>Methotrexate (N/%)</th>
<th>Sulfasalazine (N/%)</th>
<th>Infliximab (N/%)</th>
<th>Etanercept (N/%)</th>
<th>Adalimumab (N/%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enteroarthritis</td>
<td>21/43.8%</td>
<td>17/37.4%</td>
<td>30/62.5%</td>
<td>14/29.2%</td>
<td>38/79.2%</td>
<td>12/25.0%</td>
<td>1/2.1%</td>
<td>-/0%</td>
</tr>
<tr>
<td>Spondyloarthritis</td>
<td>994/68.2%</td>
<td>1,009/69.3%</td>
<td>504/34.6%</td>
<td>766/52.6%</td>
<td>630/43.2%</td>
<td>218/15.0%</td>
<td>43/3.0%</td>
<td>34/2.3%</td>
</tr>
<tr>
<td>P</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.001</td>
<td>&lt; 0.001</td>
<td>0.057</td>
<td>0.725</td>
<td>0.284</td>
</tr>
</tbody>
</table>

**NSAIDs**, non-steroidal anti-inflammatory drugs.  
*The medication was considered effective if it improved pain after 48 hours of its onset and/or resulted in rapid pain worsening after 48 hours of withdrawal, regardless of the subclass or dose regimen.

### Discussion

The enteroarthritides, classified within the group of spondyloarthritides, have peculiar characteristics that differ in some aspects from idiopathic ankylosing spondylitis and other diseases in this group. In this study, a small predominance of the female gender was observed among patients with enteropathic arthritis, in contrast with other types of spondyloarthritis (where the male/female ratio approaches 3:1). The findings are consistent with the results of studies that found a balance or higher frequency in the female gender, although some authors found a male predominance even among patients with enteropathic arthritis.

These discrepancies may reflect population differences, but above all, they can be related to the fact that some of the aforementioned studies did not subdivide their patients into more specific groups, such as axial or peripheral involvement, or did not consider only patients with enteropathic arthritis, but also individuals with inflammatory bowel disease without joint involvement, which in practice greatly diminishes the validity of the comparison.

Regarding the clinical presentation, no significant differences were observed between the groups with enteropathic arthritis and other types of spondyloarthritis. In both groups, there was a predominance of mixed form in approximately...
50% of patients, followed by axial and peripheral forms, and less frequently, the enthesitic form. These data are similar to those found in other studies.\textsuperscript{17,18,19}

A less severe axial involvement was observed in patients with enteropathies when compared to individuals with other types of spondyloarthritis, verified by the lower prevalence of inflammatory axial pain, better rates of mobility in the lumbo-sacral spine, lower frequency of radiographic sacroiliitis, and lower BASRI scores (lower radiographic damage). Nevertheless, no difference was observed between measures of functional capacity, disease activity and quality of life. However, this finding does not necessarily indicate a more “benign” nature of IBD-related spondylitis, as it may be due to the difference in time of evolution between the two groups in this sample (on average, patients with enteropathic arthritis had approximately four years and six months less time of symptoms than the others). Some authors have found a positive association between the duration of bowel disease and the likelihood of developing extraintestinal manifestations, reinforcing this hypothesis.\textsuperscript{9,10,40} A number of case series are consistent with the finding of lower radiographic grade in patients with IBD, even in symptomatic axial disease.\textsuperscript{29,30,42} In other studies, however, the radiographic classification of severity was similar between classical and enteropathic spondylitis.\textsuperscript{43,44}

When comparing the frequency of radiographic sacroiliitis among patients with enteropathic arthritis in the current sample (60%) with several other studies (20% to 61%),\textsuperscript{17,19,20,21,45} a high frequency of these alterations was confirmed, even without a clear clinical correlation, i.e., no history of pain in the buttocks or lumbar region, constituting what some authors call subclinical or asymptomatic sacroiliitis.\textsuperscript{6,7,40,41,46,48,49} Nevertheless, the comparison of these data is possibly flawed, given the great variation among the selected populations, imaging methods used, the criteria used, and the observers according to different studies - many of which were multicenter, including the present study.

This study also found a lower prevalence of HLA-B27 in individuals with enteropathies when compared to other types of spondyloarthritis (38.5% vs. 70.1%; P = 0.001), although this difference decreases when the subgroup with pure axial involvement (IBD-related spondylitis), in which the presence of this antigen reaches 47.6, is analyzed separately. Among those classified as having the pure peripheral form that were tested, none had it. The results are consistent with those of studies that found a higher prevalence of HLA-B27 in patients with IBD and axial form than in patients without the axial form (albeit at a lower frequency when compared to that found in idiopathic ankylosing spondylitis).\textsuperscript{30,17,25,40,48,50}

However, the population frequency of the allele should always be considered when interpreting data on the prevalence of genetic markers, which may explain discrepancies between different studies with different populations.\textsuperscript{35,51}

Regarding the medications, the lower frequency of use of NSAIDs and higher use of corticosteroids have also been observed in other studies,\textsuperscript{17,50} and probably reflect the fear of administering NSAIDs to patients with IBD at risk of exacerbation of bowel symptoms. This risk, however, has no consensus regarding its real magnitude.\textsuperscript{52}

In the present study, differences between patients with enteropathies and other spondyloarthritides were observed, especially higher prevalence in females, and lower frequency of HLA-B27, even in those with the pure axial form and associated with the lower degree of severity of axial involvement. These peculiarities should be taken into account when managing patients with IBD and musculoskeletal complaints.

**Conflicts of interest**

The electronic version of the Brazilian Registry of Spondyloarthritides is supported by a grant from Wyeth/Pfizer Brazil, which had no influence on the collection and analysis of data or in the writing and publication of articles. Percival Sampaio-Barros received a research grant from the Federico Foundation.

**Erratum**

In the original article “Enteropathic arthritis in Brazil: data from the Brazilian registry of spondyloarthritides” (Rev Bras Reumatol 2013;53(6):452-459), where it reads:

Gustavo G. Resende*, Cristina C. D. Lamara, Adriana B. Bortoluzzo\textsuperscript{3}, Célia R. Gonçalves\textsuperscript{2}, Percival D. Sampaio-Barros\textsuperscript{4}, José Antonio Braga da Silvab, Antonio Carlos Ximenes\textsuperscript{1}, Manoel B. Bértoloc, Sandra L.E. Ribeiro\textsuperscript{1}, Mauro Keiserman\textsuperscript{3}, Rita Menirini, Thelma L. Skare\textsuperscript{1}, Sueli Carneiro\textsuperscript{a}, Valderílio A. Azevedod, Walber P. Vieira\textsuperscript{a}, Elisa N. Albuquerque\textsuperscript{b}, Washington A. Bianchi\textsuperscript{c}, Rubens Bonfigliolib, Cristianon Campanholo, Hellen M. S. Carvalhod, Izaias P. Costa\textsuperscript{a}, Angela P. Duarte\textsuperscript{a}, Charles L. Kohem, Nocy Leite, Sonia A. L. Lima\textsuperscript{a}, Eduardo S. Meirelles\textsuperscript{a}, Ivânoí A. Pereiraa, Marcelo M. Pinheirao, Elizandra Polito\textsuperscript{a}, Francisco Airtton C. Rocha, Mittermayer B. Santiago\textsuperscript{d}, Maria de Fátima L. C. Saumaa, Valeria Válmima

* Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

\textsuperscript{1} Instituto Inserp de Educação e Pesquisa, São Paulo, SP, Brazil

\textsuperscript{2} Disciplina de Reumatologia, Universidade de São Paulo, São Paulo, SP, Brazil

\textsuperscript{3} Universidade de Brasília, Brasília, DF, Brazil

\textsuperscript{4} Hospital Geral de Goiânia, Goiânia, GO, Brazil

\textsuperscript{5} Universidade de Campinas, Campinas, SP, Brazil

\textsuperscript{6} Universidade Federal do Amazonas, Manaus, AM, Brazil

\textsuperscript{7} Pontifícia Universidade Católica, Porto Alegre, RS, Brazil

\textsuperscript{8} Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil

\textsuperscript{9} Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

\textsuperscript{10} Universidade Federal do Mato Grosso do Sul, Campo Grande, MS, Brazil

\textsuperscript{11} Universidade Federal de Pernambuco, Recife, PE, Brazil

\textsuperscript{12} Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
REFERENCES


